Beverly Stoudemire Howlett, MD
Cardiovascular Disease · Montgomery, ALNPI 1891766630
Payments from drug & device makers
Across 375 payments — averaging $19.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$908
- Novartis$571
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$554
- Alnylam Pharmaceuticals Inc.$551
- Amgen$500
- AstraZeneca$484
- plus $4K from 29 others
What the payments were for
- Food & beverage$7,299100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 51 | $908 |
| Novartis | 39 | $571 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 31 | $554 |
| Alnylam Pharmaceuticals Inc. | 20 | $551 |
| Amgen | 25 | $500 |
| AstraZeneca | 27 | $484 |
| Merck | 21 | $438 |
| E.r. Squibb & Sons, L.L.C. | 26 | $419 |
| Boehringer Ingelheim | 20 | $401 |
| Actelion Pharmaceuticals US, Inc. | 17 | $331 |
| Sanofi-aventis U.S. LLC | 16 | $326 |
| Arbor Pharmaceuticals, Inc. | 12 | $255 |
| Amarin Pharma, Inc. | 12 | $224 |
| Abbott | 5 | $158 |
| Regeneron Healthcare Solutions, Inc. | 5 | $116 |
| Medtronic(2 entities) | 5 | $113 |
| Johnson & Johnson | 7 | $109 |
| Braemar Manufacturing, LLC | 1 | $94 |
| Novo Nordisk | 5 | $92 |
| Gilead | 4 | $84 |
| Viiv Healthcare Company | 1 | $74 |
| Bridgebio Pharma, Inc. | 3 | $62 |
| Impulse Dynamics (USA) Inc. | 2 | $57 |
| United Therapeutics Corporation | 3 | $48 |
| Philips North America LLC | 2 | $48 |
| Lexicon Pharmaceuticals, Inc. | 2 | $47 |
| Kowa Pharmaceuticals America, Inc. | 3 | $41 |
| Sanofi | 1 | $38 |
| Esperion Therapeutics, Inc. | 2 | $31 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $31 |
| Scpharmaceuticals Inc. | 2 | $29 |
| Edwards Lifesciences | 1 | $24 |
| Celonova Biosciences, Inc. | 1 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Sobi, Inc | 1 | $16 |
How this compares
$7,313 in reported general payments places this provider in the 70th percentile of 292 cardiovascular disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 17 | $398,622 |
| EliquisApixaban | 361 | $364,304 |
| EntrestoSacubitril/Valsartan | 318 | $354,740 |
| OpsumitMacitentan | 12 | $175,767 |
| MultaqDronedarone Hcl | 67 | $96,444 |
| FarxigaDapagliflozin Propanediol | 70 | $63,549 |
| JardianceEmpagliflozin | 35 | $52,181 |
| VascepaIcosapent Ethyl | 87 | $50,538 |
| XareltoRivaroxaban | 41 | $48,715 |
| Repatha SureclickEvolocumab | 65 | $48,282 |
| BrilintaTicagrelor | 63 | $42,830 |
| Icosapent Ethyl | 80 | $30,191 |
| Ranolazine ErRanolazine | 144 | $17,035 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 27 | $10,695 |
| EdarbiAzilsartan Medoxomil | 18 | $8,468 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $908 | $762,926378 claims |
| NovartisEntresto | $571 | $354,740318 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $331 | $175,76712 claims |
| AstraZenecaFarxiga, Brilinta | $484 | $106,379133 claims |
| Sanofi-aventis U.S. LLCMultaq | $326 | $96,44467 claims |
| Boehringer IngelheimJardiance | $401 | $52,18135 claims |
| Johnson & JohnsonXarelto | $109 | $48,71541 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi | $255 | $19,16345 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 292 cardiovascular disease providers in Alabama.
Other cardiovascular disease in Montgomery
- Mustafa AhmedBirmingham$2.5M
- Brian FoleyAlexander City$2.5M
- Andreas MuenchDothan$2M
- Alain BouchardBirmingham$1.9M
- William DavisAuburn$1.7M
- Walter HaughtHuntsville$1.6M
- Christopher BrownMobile$1.4M
- Shi-Chi ChengHuntsville$1.2M
- Mahomed SalameAnniston$1.2M
- Steven JonesBirmingham$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.